Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer
January 07, 2016 09:24 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
December 10, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
November 20, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with...
Capsules de JUXTAPIDMC (lomitapide) disponibles sur la Liste des médicaments de la Régie de l'assurance maladie du Québec (RAMQ) pour le traitement de l’hypercholestérolémie familiale homozygote (HFHo)
November 20, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc., société biopharmaceutique se consacrant à l’élaboration et à la commercialisation de thérapies innovantes pour des patients...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
November 20, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
Aegerion Pharmaceuticals to Present at the Jefferies Autumn 2015 Global Healthcare Conference
November 13, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Results From First Year of LOWER Study at AHA Scientific Sessions 2015
November 10, 2015 16:35 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Third Quarter 2015 Financial Results
November 09, 2015 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
- Company records $67.3 million in total net product sales - CAMBRIDGE, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company...
Aegerion Pharmaceuticals Announces Postponement of Third Quarter 2015 Financial Results Conference Call
November 05, 2015 08:20 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals to Announce Third Quarter 2015 Financial Results on Thursday, November 5
October 29, 2015 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...